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In 2006, the American Heart Association Expert Consensus
Panel proposed a new definition of cardiomyopathies (1):
Cardiomyopathies are a heterogeneous group of diseases of the
myocardium associated with mechanical and/or electrical dys-
function that usually (but not invariably) exhibit inappropriate
ventricular hypertrophy or dilatation and are due to a variety of
causes that frequently are genetic. Cardiomyopathies either are
confined to the heart or are part of generalized systemic
disorders, often leading to cardiovascular death or progressive
heart failure–related disability.
The panelists make the point that (1):
. . . some diseases do not have a uniformly static expression
and may evolve, as a consequence of remodeling, from one
category to another during their natural clinical course; eg,
hypertrophic cardiomyopathy, amyloid, and other infiltra-
tive conditions may progress from a nondilated (often
hyperdynamic) state with ventricular stiffness to a dilated
form with systolic dysfunction and failure.
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Etiologies of cardiomyopathy include one or more of the follow-
ing: genetics (about 20% of patients with idiopathic dilated
cardiomyopathy have a relative with decreased ejection fraction),
inflammation, infection, post-partum state, tachycardia, exposure
to cardiotoxic agents (e.g., mediastinal radiation, chemotherapy
with agents like doxorubicin or antibody therapy with trastu-
zumab), consumption of alcohol, and idiopathic causes (2). Re-
gardless of etiology, injury to the myocardium impairs myocardial
contractility, resulting in heart failure.
Dilated cardiomyopathy accounts for 25% of patients
with heart failure in the United States (3). Patients with
dilated cardiomyopathy in heart failure have a mortality
ranging from 10% to 50%/yr (4). Patients with a treatable
etiology often have a good prognosis for stabilization or
improvement in function. In contrast, patients without a
defined etiology are at risk of progressive disease. Decreased
systolic function is usually treated with medical therapy (5).
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35% or wide QRS complexes, either resynchronization
therapy or an implanted cardiac defibrillator may be neces-
sary. Despite therapy, some patients have progressive heart
failure requiring a heart transplant.
A universal manifestation of cardiomyopathy is a decrease
in contractile performance. Cardiac histopathology demon-
strates marked alterations in the appearance of the contrac-
tile apparatus and in the appearance and location of mito-
chondria within the myocyte. A study of explanted hearts of
patients with dilated myopathy undergoing transplantation
demonstrated that “mitochondria occurred in large clusters
in cytoplasm free of myofibrils, and they varied in size and
shape from very small to very large. [There was a] lack of
myofibrils in many cellular areas, in the center and in the
periphery of a myocyte. Next to hypertrophied cells, other
cells were atrophic” (6).
This appearance suggests that the mitochondria could not
transfer high-energy phosphate efficiently, even if the mi-
tochondria were working normally. As a result, assessing
mitochondrial function could provide information about the
performance of the heart as a muscle.
Myocardial mitochondria have the daunting task of produc-
ing about 30 kg/d of adenosine triphosphate (ATP) to maintain
function (7). To meet this demand there must be continuous
delivery of substrate to the mitochondria, the mitochondria
must have adequate oxidative capacity, and the cell must have
an effective transfer system of ATP from the mitochondria to
sites of utilization (8). Based on the histopathology of the
explanted hearts, it is likely that both the energy-producing and
energy-transfer components of mitochondria cannot function
normally in the myopathic heart.
One parameter that reflects mitochondrial function is the
transmembrane potential (TMP) of the mitochondria (9).
Under normal circumstances, mitochondria have the most
electronegative potential of the organelles in the myocyte
and therefore are the site of localization of charged lipo-
philic molecules that pass through the sarcolemma. Reten-
tion of these agents in the cell is proportional to TMP, and
loss of TMP results in loss of the indicator. In vitro,
multiple dyes can be used to determine mitochondrial
function; in vivo, the choices are more limited.
The lipophilic cationic myocardial perfusion agent,
technetium-99m methoxyisobutylisonitrile (MIBI) localizes
primarily in mitochondria (10). The positively charged
fat-soluble molecule traverses the myocardial sarcolemma,
enters the cell, and localizes in the highly electronegative
mitochondria. MIBI is retained in the mitochondria by the
higher membrane potential. Loss of mitochondrial mem-
brane potential results in rapid loss of MIBI from the
myocyte (11,12). Investigators have tested the relationships
of MIBI washout to mechanical dysfunction and prognosis.
Matsuo et al. (13) evaluated 61 patients with nonischemic
congestive heart failure. The myocardial washout rate
(WR), calculated from planar images, correlated with the
level of B-type naturetic peptide, increased with increasing
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with LVEF. Over a mean follow-up of 12 months (range: 1
to 19 months), patients with a WR 28% had more events
than did subjects with lower WR. Isobe et al. (14) studied
24 patients with hypertrophic myopathy. The investigators
recorded planar and single-photon emission computed to-
mographic MIBI images following injection at rest. The
heart-to-mediastinal ratio was calculated from planar im-
ages recorded at 40 min and at 4 h. The investigators found
increased MIBI loss from the myocardium in patients with
elevated left ventricular end-diastolic pressure and pro-
longed half-time of relaxation. In 17 patients with dilated
cardiomyopathy (mean LVEF: 29%), Shiroodi et al. (15)
measured MIBI washout and compared the results to those
from 6 normal subjects (mean LVEF: 66%). The investi-
gators acquired images at 30 min and 3.5 h after injection.
Regions of interest placed in the mediastinum and the entire
LV myocardium on an anterior planar view were used to
etermine the washout in the 3-h interval between images.
ardiomyopathy patients had a WR of 29.13 versus 14.17 for
ontrols. WRs increased from 23.16 for patients with NYHA
lass I, 30.25 for class II, 32.60 for class III, and 37.5 for class
V. WR was negatively correlated with LVEF (r2  0.679).
In this issue of the Journal,Hayashi et al. (16) add significant
information to these observations. The investigators studied 20
patients with dilated cardiomyopathy (NYHA class I, n  8;
class II, n 10; and class III, n 2; mean LVEF: 33%). The
myopathy patients did not have a history of coronary disease,
valvular disease, hypertension, chronic atrial fibrillation, or
diabetes. All myopathy subjects had cardiac catheterization
with coronary angiography, dobutamine infusion to detect
changes in maximum first derivative of LV pressure (LV
dP/dtmax), endocardial biopsy (to exclude myocarditis), and
everse transcriptase–polymerase chain reaction (RT-PCR) of
he biopsy specimen; 6 subjects had electron microscopy of the
iopsy specimen. The electron microscopy specimens had
uantitation of the number and size of mitochondria and the
everity of mitochondrial degeneration.
Hayashi et al. (16) used a slightly different protocol than did
hiroodi et al. (15), recording MIBI images at 1 and 4 h after
njection. Myocardial retention of MIBI was measured on
lanar images as: (initial net myocardial counts* – delayed net
yocardial counts†)/initial net myocardial counts.
Despite minor differences in technique, the results were
similar. Overall, Matsuo, Isobe, Shiroodi, and Hayashi
found a decrease in myocardial MIBI retention in myopathy
patients compared with those in control patients.
Hayashi divided the myopathy patients into two groups
based on the WR. The group with a greater WR had a
reduction in the abundance of mRNAs for mitochondrial
electron transport-related enzymes on RT-PCR and more
extensive mitochondrial damage on electron microscopy.
Although the number of subjects was small, the data
suggest that adding a simple measurement to a myocardial
*Corrected for mediastinal background.
†Corrected for both mediastinal background and decay.perfusion scan can provide information about mitochondrial
status. As stated by Ventura-Clapier et al. (8), “Despite the
diversity of origin and of clinical manifestation of heart
failure, defects in energy metabolism are increasingly con-
sidered as an important determinant in the progression of
the disease.” Hayashi et al. (16) have done an excellent job
demonstrating the anatomic and functional correlation of
the MIBI WR. Now it is up to the Nuclear Cardiology
community to utilize this additional measurement, to define
its role in patient management.
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